217 related articles for article (PubMed ID: 16014176)
1. Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.
Harr MW; Graves TG; Crawford EL; Warner KA; Reed CA; Willey JC
Mol Cancer; 2005 Jul; 4():23. PubMed ID: 16014176
[TBL] [Abstract][Full Text] [Related]
2. Stable low-level expression of p21WAF1/CIP1 in A549 human bronchogenic carcinoma cell line-derived clones down-regulates E2F1 mRNA and restores cell proliferation control.
Graves TG; Harr MW; Crawford EL; Willey JC
Mol Cancer; 2006 Jan; 5():1. PubMed ID: 16403226
[TBL] [Abstract][Full Text] [Related]
3. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
Tophkhane C; Yang SH; Jiang Y; Ma Z; Subramaniam D; Anant S; Yogosawa S; Sakai T; Liu WG; Edgerton S; Thor A; Yang X
PLoS One; 2012; 7(8):e43564. PubMed ID: 22952705
[TBL] [Abstract][Full Text] [Related]
4. p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability.
Yan W; Zhang J; Zhang Y; Jung YS; Chen X
Mol Cell Biol; 2012 Jul; 32(13):2336-48. PubMed ID: 22508983
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the p53 homolog p73 by adenoviral oncogene E1A.
Das S; El-Deiry WS; Somasundaram K
J Biol Chem; 2003 May; 278(20):18313-20. PubMed ID: 12639967
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73.
Dietz S; Rother K; Bamberger C; Schmale H; Mössner J; Engeland K
FEBS Lett; 2002 Aug; 525(1-3):93-9. PubMed ID: 12163168
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
Million K; Horvilleur E; Goldschneider D; Agina M; Raguénez G; Tournier F; Bénard J; Douc-Rasy S
Int J Oncol; 2006 Jul; 29(1):147-54. PubMed ID: 16773194
[TBL] [Abstract][Full Text] [Related]
8. Deregulated expression of E2F1 promotes proteolytic degradation of tumor suppressor p73 and inhibits its transcriptional activity.
Ozaki T; Okoshi R; Ono S; Kubo N; Nakagawara A
Biochem Biophys Res Commun; 2009 Sep; 387(1):143-8. PubMed ID: 19576172
[TBL] [Abstract][Full Text] [Related]
9. [Effect of 14-3-3sigma on transcriptional activity of p73 gene].
Sang MX; Geng CZ; Shan BE
Ai Zheng; 2007 May; 26(5):489-93. PubMed ID: 17672938
[TBL] [Abstract][Full Text] [Related]
10. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript.
Pützer BM; Tuve S; Tannapfel A; Stiewe T
Cell Death Differ; 2003 May; 10(5):612-4. PubMed ID: 12728260
[No Abstract] [Full Text] [Related]
11. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
12. The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells.
DeMuth JP; Jackson CM; Weaver DA; Crawford EL; Durzinsky DS; Durham SJ; Zaher A; Phillips ER; Khuder SA; Willey JC
Am J Respir Cell Mol Biol; 1998 Jul; 19(1):18-24. PubMed ID: 9651176
[TBL] [Abstract][Full Text] [Related]
13. p73alpha expression induces both accumulation and activation of wt-p53 independent of the p73alpha transcriptional activity.
Miro-Mur F; Meiller A; Haddada H; May E
Oncogene; 2003 Aug; 22(35):5451-6. PubMed ID: 12934105
[TBL] [Abstract][Full Text] [Related]
14. Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1.
Wu S; Murai S; Kataoka K; Miyagishi M
Biochem Biophys Res Commun; 2008 Jan; 365(1):75-81. PubMed ID: 17980704
[TBL] [Abstract][Full Text] [Related]
15. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.
Alla V; Kowtharapu BS; Engelmann D; Emmrich S; Schmitz U; Steder M; Pützer BM
Cell Cycle; 2012 Aug; 11(16):3067-78. PubMed ID: 22871739
[TBL] [Abstract][Full Text] [Related]
16. Two new p73 splice variants, gamma and delta, with different transcriptional activity.
De Laurenzi V; Costanzo A; Barcaroli D; Terrinoni A; Falco M; Annicchiarico-Petruzzelli M; Levrero M; Melino G
J Exp Med; 1998 Nov; 188(9):1763-8. PubMed ID: 9802988
[TBL] [Abstract][Full Text] [Related]
17. Kinase activity-independent suppression of p73alpha by AMP-activated kinase alpha (AMPKalpha).
Lee YG; Lee SW; Sin HS; Kim EJ; Um SJ
Oncogene; 2009 Feb; 28(7):1040-52. PubMed ID: 19079340
[TBL] [Abstract][Full Text] [Related]
18. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
[TBL] [Abstract][Full Text] [Related]
19. Regulation of telomerase activity by the p53 family member p73.
Beitzinger M; Oswald C; Beinoraviciute-Kellner R; Stiewe T
Oncogene; 2006 Feb; 25(6):813-26. PubMed ID: 16205639
[TBL] [Abstract][Full Text] [Related]
20. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]